TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  The Motley Fool

Supernus Stock Is Up 31% This Past Year but Still 20% Below 2018 Highs as One Fund Scales Back

The Motley Fool Logo The Motley Fool By Jonathan Ponciano
Supernus Stock Is Up 31% This Past Year but Still 20% Below 2018 Highs as One Fund Scales Back

Aristotle Capital Boston reduced its holdings in Pharmaceuticals by 503,122 shares in Q3, decreasing its position value by approximately $10.9 million. Despite a 31% stock price increase over the past year, the company remains below its 2018 highs.

Insights
SUPN   neutral

The stock has shown positive performance with 31% growth, but faces challenges with uneven profitability and remains below historical highs. The fund's partial sell-off suggests cautious investor outlook.